We observed that IGF2BP2 and IGF2BP3 expression was markedly upregulated in the central nervous system (CNS), lung, gastric tract, head, neck, pancreas, and lymphatic system cancers (Figure S1A). This evidence concerns the gene IGF2BP3 and lymphatic system cancer.